Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Latest (Page 7)
Fucoidan Boosts Quality of Life for Rectal Cancer Patients During Treatment
Study finds fucoidan supplement improves physical well-being in rectal cancer patients receiving chemoradiation
Blood Test Predicts Immunotherapy Response in Lung Cancer Patients
Study shows ctDNA blood test can predict immunotherapy response in advanced lung cancer patients
Identifying High-Risk Prostate Cancer Patients for Treatment Escalation
Study finds factors predicting early PSA failure in prostate cancer, suggesting need for more aggressive treatment
Olaparib Rechallenge Offers Hope for Relapsed Ovarian Cancer Patients
Study shows olaparib rechallenge improves progression-free survival in platinum-sensitive relapsed ovarian cancer
New Hope for Liver Cancer: Tislelizumab Shows Promise as First-Line Treatment
Study finds tislelizumab comparable to sorafenib for unresectable hepatocellular carcinoma treatment
Daratumumab Combo Shows Promise for Relapsed Multiple Myeloma
Study finds adding daratumumab to pomalidomide and dexamethasone improves survival in multiple myeloma
New Myeloma Treatment Shows Promise, But Falls Short of Expectations
Study finds belantamab mafodotin matches standard therapy for multiple myeloma, with fewer infections
Hypofractionated vs. Conventional Radiotherapy for Glioblastoma: A Comparative Study
Study compares hypofractionated and conventional radiotherapy with temozolomide for glioblastoma patients
Natural Compounds Show Promise in Colorectal Cancer Prevention
Study explores effects of curcumin and anthocyanins on biomarkers in patients with colorectal adenomas
Synbiotics Show Promise in Easing Chemotherapy Side Effects for Breast Cancer Patients
Study finds synbiotic supplements may reduce fatigue, GI issues in breast cancer patients on chemotherapy
Shorter Trastuzumab Treatment Shows Promise for Early HER2+ Breast Cancer
9-week trastuzumab regimen nearly matches 1-year in long-term outcomes for early HER2+ breast cancer
Vincristine Infusion Time Does Not Affect Neuropathy in Pediatric Cancer
Study finds no difference in neuropathy between 1-hour and push injection of vincristine in children with cancer